CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts

Conclusions: Our results indicate that locally administered CpG-ODN1826 is able to markedly affect the growth of both early- and late-stage DMPM orthotopic xenografts in the absence of severe side effects, and suggest a possible clinical role for the agent in the therapy of DMPM. (Source: Journal of Translational Medicine)

from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=163454494&cid=c_409_39_f&fid=32101&url=http%3A%2F%2Fwww.translational-medicine.com%2Fcontent%2F14%2F1%2F25